ISIS Pharmaceuticals, Inc.  

(Public, NASDAQ:ISIS)   Watch this stock  
Find more results for ISIS
+1.76 (3.31%)
Jul 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 52.80 - 55.56
52 week 29.17 - 77.80
Open 53.53
Vol / Avg. 1.59M/2.41M
Mkt cap 6.58B
P/E     -
Div/yield     -
EPS -0.21
Shares 119.71M
Beta 1.58
Inst. own 85%
Aug 4, 2015
Q2 2015 Isis Pharmaceuticals Inc Earnings Call - 11:30AM EDT - Add to calendar
Aug 4, 2015
Q2 2015 Isis Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
Jun 30, 2015
Isis Pharmaceuticals Inc Annual Shareholders Meeting
Jun 11, 2015
Isis Pharmaceuticals Inc to Discuss Data From ISIS-SMN Rx Phase 2 Study in Infants With Spinal Muscular Atrophy
Jun 10, 2015
Isis Pharmaceuticals Inc at Goldman Sachs Healthcare Conference
Jun 4, 2015
Isis Pharmaceuticals Akcea Therapeutics Conference Call - Webcast
May 19, 2015
Isis Pharmaceuticals Inc at UBS Global Healthcare Conference
May 12, 2015
Isis Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Isis Pharmaceuticals Inc at Deutsche Bank Health Care Conference
May 5, 2015
Q1 2015 Isis Pharmaceuticals Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -26.71% -18.20%
Operating margin -14.91% -26.16%
EBITD margin - -17.90%
Return on average assets -7.02% -4.32%
Return on average equity -25.13% -12.26%
Employees 390 -
CDP Score - -


2855 Gazelle Ct
CARLSBAD, CA 92010-6670
United States - Map
+1-760-9319200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Isis Pharmaceuticals, Inc. (Isis) is a Ribonucleic acid-targeted (RNA-targeted) drug discovery and development company. The Company is focused to discover and develop antisense drugs. The antisense drugs are used to treat a range of diseases, including cardiovascular, metabolic, severe and rare diseases, including neurological disorders and cancer. ISIS-APOCIII is a drug indicated to to treat patients with high triglyceride levels, including patients with a genetic condition called familial chylomicronemia syndrome (FCS) and patients with partial lipodystrophy. In addition to ISIS-APOCIII, it is also evaluating ISIS-TTR and ISIS-SMN in Phase III studies. Its lipid-lowering product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia (HoFH).

Officers and directors

Stanley T. Crooke M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 69
Bio & Compensation  - Reuters
Elizabeth L. Hougen Chief Financial Officer, Senior Vice President - Finance
Age: 53
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Chief Operating Officer, Corporate Secretary, Director
Age: 61
Bio & Compensation  - Reuters
Patrick R. O'Neil Esq. Senior Vice President - Legal, General Counsel
Age: 41
Bio & Compensation  - Reuters
C. Frank Bennett Ph.D. Senior Vice President - Antisense Research
Age: 58
Bio & Compensation  - Reuters
Richard S. Geary Ph.D. Senior Vice President - Development
Age: 57
Bio & Compensation  - Reuters
Brett P. Monia Ph.D. Senior Vice President - Drug Discovery and Corporate Development
Age: 53
Bio & Compensation  - Reuters
Sarah Boyce Chief Business Officer
Age: 43
Bio & Compensation  - Reuters
Joseph Loscalzo M.D., Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
Spencer R. Berthelsen M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters